These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 34821004)
1. Patients on emicizumab prophylaxis with previously tolerized inhibitors: Is there a risk of inhibitors recurrence? Hassan E; Lancashire J; Motwani J Haemophilia; 2022 Mar; 28(2):e36-e38. PubMed ID: 34821004 [No Abstract] [Full Text] [Related]
2. Real-world data on emicizumab prophylaxis in the Milan cohort. Arcudi S; Gualtierotti R; Marino S; Nicolò G; Biguzzi E; Ciavarella A; Boscarino M; Siboni SM; Schiavone L; Novembrino C; Valsecchi C; Peyvandi F Haemophilia; 2022 Sep; 28(5):e141-e144. PubMed ID: 35853212 [No Abstract] [Full Text] [Related]
3. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146 [TBL] [Abstract][Full Text] [Related]
4. Development of VIII inhibitors beyond 50 exposure days to rFVIII during prophylactic emicizumab therapy. Mitani Y; Honda M; Mizushima Y; Mori M; Fukuoka K; Oshima K; Arakawa Y; Taira K; Tanami Y; Koh K Haemophilia; 2023 Nov; 29(6):1653-1655. PubMed ID: 37707369 [No Abstract] [Full Text] [Related]
5. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A. Le Quellec S Drug Des Devel Ther; 2020; 14():469-481. PubMed ID: 32099331 [TBL] [Abstract][Full Text] [Related]
6. A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures. Escobar M; Dunn A; Quon D; Trzaskoma B; Lee L; Ko RH; Carpenter SL Haemophilia; 2022 Jul; 28(4):e105-e108. PubMed ID: 35510949 [No Abstract] [Full Text] [Related]
7. Switching to emicizumab: A prospective surveillance study in haemophilia A subjects with inhibitors. Dubé E; Merlen C; Bonnefoy A; Pilon J; Zourikian N; Gauthier J; St-Louis J; Rivard GÉ Haemophilia; 2023 Jan; 29(1):348-351. PubMed ID: 36315386 [No Abstract] [Full Text] [Related]
8. Prophylaxis with emicizumab in children under 12 years old with haemophilia A without inhibitors in Uruguay: National experience. Lemos F; Petraccia C; Fraga ML; Casuriaga AL; Lutz S; Gómez R; Giachetto G; Boggia B Haemophilia; 2024 Jul; 30(4):1077-1079. PubMed ID: 38684449 [No Abstract] [Full Text] [Related]
9. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389 [TBL] [Abstract][Full Text] [Related]
10. Transplacental transfer of emicizumab: Experience with emicizumab in a pregnant female with severe hemophilia A and an inhibitor. Kharel Z; Pruthi RK; Kouides P; Reid R Haemophilia; 2024 May; 30(3):868-871. PubMed ID: 38650315 [No Abstract] [Full Text] [Related]
11. Interferences by factor VIII and lupus anticoagulant in the modified one-stage assay for emicizumab. Habay C; Auditeau C; Blandinières A; Bentounes NK; Lavenu-Bombled C; Harroche A; Bally C; Frenzel L; Borgel D; Lasne D Haemophilia; 2023 Nov; 29(6):1661-1664. PubMed ID: 37751318 [No Abstract] [Full Text] [Related]
12. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A. Díaz-Ricart M; Isola IM; Escolar G Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480 [TBL] [Abstract][Full Text] [Related]
13. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557 [TBL] [Abstract][Full Text] [Related]
14. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events. Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050 [No Abstract] [Full Text] [Related]
15. Emicizumab assays evaluations with four different reagents in severe haemophilia A patients: Concentration from baseline to maintenance therapy. Launois A; De Raucourt E; Martin-Toutain I; Samdjee F; Le Dore S; Ferre E; Flaujac C Haemophilia; 2023 Jan; 29(1):374-376. PubMed ID: 36446748 [No Abstract] [Full Text] [Related]
16. Paradigm shifts in haemophilia A therapy with emicizumab prophylaxis in Asia. Sosothikul D; Moonla C Ann Acad Med Singap; 2023 Nov; 52(11):556-558. PubMed ID: 38920143 [No Abstract] [Full Text] [Related]
17. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X. Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217 [TBL] [Abstract][Full Text] [Related]
18. Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring. Biron-Andreani C; Diaz-Cau I; Ranc A; Navarro R; Leonardi C; Dischino M; Guy R; Theron A; Garcia-Gournay C; Santagostino E; Schved JF Br J Haematol; 2020 May; 189(3):e100-e103. PubMed ID: 32087028 [No Abstract] [Full Text] [Related]
19. Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis. Doshi BS; Witmer CM Haemophilia; 2021 Jul; 27(4):e551-e553. PubMed ID: 33866659 [No Abstract] [Full Text] [Related]
20. Do we need all that emicizumab? Lehtinen AE; Lassila R Haemophilia; 2022 Mar; 28(2):e53-e55. PubMed ID: 34970820 [No Abstract] [Full Text] [Related] [Next] [New Search]